In vitro controlled release of antigen in dendritic cells using pH-sensitive liposome-polymeric hybrid nanoparticles

Hu, Yun; Zhao, Zongmin; Ehrich, Marion; Fuhrman, Kristel; Zhang, Chenming

doi:10.1016/j.polymer.2015.10.048

Cited by 28 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20, 22] The lipid film containing 0.25 mg MPLA, 2.83 mg DOTAP, 3.08 mg (DSPE-PEG2000) carboxylic acid, and 0.1 mg cholesterol was hydrated with 1 mL of 55 °C pre-warmed PBS buffer. The resulting liposome suspension was vigorously mixed using a vortex mixer for 2 min, followed by sonication for 5 min, using a Branson B1510DTH Ultrasonic Cleaner (Branson, Danbury, CT) and then cooled to room temperature.…”

Section: Methodsmentioning

confidence: 99%

The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine

Smith

Frazier

et al. 2016

Biomaterials

Self Cite

View full text Add to dashboard Cite

Owing to the urgent need for more effective treatment against nicotine addiction, a hybrid nanoparticle-based nicotine vaccine (NanoNiccine) was developed in this study. NanoNiccine was composed of a poly(lactide-co-glycolide) acid (PLGA) core, keyhole limpet hemocyanin (KLH) as an adjuvant protein enclosed within the PLGA core, a lipid layer, and nicotine haptens conjugated to the outer surface of the lipid layer. In contrast to the traditional nicotine vaccine, NanoNiccine is not a nicotine-protein conjugate vaccine. Instead, the nicotine hapten and protein are separately located in the nanostructure to minimize antibody production towards KLH. The cellular uptake study demonstrated that NanoNiccine was ideal for internalization and processing by dendritic cells (DCs). Mice immunized with NanoNiccine produced much lower IgG level against KLH as compared to that immunized with the traditional nicotine-KLH (Nic-KLH) vaccine. In addition, NanoNiccine achieved up to a 400% higher titer of anti-nicotine IgG than the positive control, Nic-KLH. Additionally, the Th1/Th2 index of NanoNiccine suggested that the immune response induced by NanoNiccine was antibody response dominant. Furthermore, NanoNiccine was found to be safe in mice.

show abstract

Section: Methodsmentioning

confidence: 99%

The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine

Smith

Frazier

et al. 2016

Biomaterials

Self Cite

View full text Add to dashboard Cite

show abstract

“…[26, 32] In brief, 2.5 mg of lipid mixture consisting of different molar ratios of DOTAP, DSPE-PEG2000-maleimide, DSPE-PEG2000-amine, and CHOL, was evaporated to form a lipid film. The lipid film was hydrated with 0.01 M phosphate buffer saline (PBS) and sonicated for 2 min to form a liposome suspension.…”

Section: Methodsmentioning

confidence: 99%

Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization

Zhao

Harmon

et al. 2017

Biomaterials

Self Cite

View full text Add to dashboard Cite

A lipid-polymeric hybrid nanoparticle-based next-generation nicotine nanovaccine was rationalized in this study to combat nicotine addiction. A series of nanovaccines, which had nicotine-haptens localized on carrier protein (LPKN), nanoparticle surface (LPNK), or both (LPNKN), were designed to study the impact of hapten localization on their immunological efficacy. All three nanovaccines were efficiently taken up and processed by dendritic cells. LPNKN induced a significantly higher immunogenicity against nicotine and a significantly lower anti-carrier protein antibody level compared to LPKN and LPNK. Meanwhile, it was found that the anti-nicotine antibodies elicited by LPKN and LPNKN bind nicotine stronger than those elicited by LPKN, and LPNK and LPNKN resulted in a more balanced Th1-Th2 immunity than LPKN. Moreover, LPNKN exhibited the best ability to block nicotine from entering the brain of mice. Collectively, the results demonstrated that the immunological efficacy of the hybrid nanoparticle-based nicotine vaccine could be enhanced by modulating hapten localization, providing a promising strategy to combatting nicotine addiction.

show abstract

“…MDA‐MB‐231 cells showed higher sensitivity to folate‐targeted‐CHEMS liposomes due to higher folate receptor expression. Similarly, Hu et al described a hybrid nanoparticle system consisting of DOPE‐based CHEMS‐liposomes and an antigen packaged within a poly(lactic‐ co ‐glycolic) acid (PLGA) core . The pH‐sensitive hybrid nanoparticle displayed faster degradation and corresponding antigen release compared to regular hybrid nanoparticle in dendritic cell (DC) cultures.…”

Section: Ph‐responsive Liposomesmentioning

confidence: 99%

Stimuli‐responsive liposomes for drug delivery

Lee

Thompson

2017

WIREs Nanomed Nanobiotechnol

371

190

View full text Add to dashboard Cite

The ultimate goal of drug delivery is to increase the bioavailability and reduce the toxic side effects of the active pharmaceutical ingredient (API) by releasing at a specific site of action. In the case of antitumor therapy, association of the therapeutic agent with a carrier system can minimize damage to healthy, non-target tissues, while limit systemic release and promoting long circulation to enhance uptake at the cancerous site due to the enhanced permeation and retention effect (EPR). Stimuli-responsive systems have become a promising way to deliver and release payloads in a site-selective manner and carrier systems have been derived from a wide variety of materials, including inorganic nanoparticles, lipids, and polymers that have been imbued with stimuli-sensitive properties to accomplish triggered release. The unique features in the tumor microenvironment can serve as an endogenous stimulus (pH, redox potential, or unique enzymatic activity) or the locus of an applied external stimulus (heat or light) to trigger the controlled release of API. Triggered release is generally based on the principle of membrane destabilization from local defects within bilayer membranes to effect release of liposome-entrapped drugs. This review focuses on the literature appearing between November 2008–February 2016 that reports new developments in stimuli-sensitive liposomal drug delivery strategies using pH change, enzyme transformation, redox reactions, and photochemical mechanisms of activation.

show abstract

In vitro controlled release of antigen in dendritic cells using pH-sensitive liposome-polymeric hybrid nanoparticles

Cited by 28 publications

References 31 publications

The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine

The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine

Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization

Stimuli‐responsive liposomes for drug delivery

Contact Info

Product

Resources

About